Brief: AB Science Authorised To Initiate Confirmatory Phase III Trial Of Masitinib In Progressive Forms Of Multiple Sclerosis
02/02/2022 17:30
Feb 2 (Reuters) - AB Science SA ABS.PA :
* REG-AB SCIENCE GRANTED AUTHORIZATION TO INITIATE
CONFIRMATORY
PHASE III TRIAL OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE
SCLEROSIS BY THE SWEDISH MEDICAL PRODUCTS AGENCY
* SWEDEN IS THE SECOND EUROPEAN COUNTRY TO AUTHORIZE THE
STUDY
AFTER THE APPROVAL RECEIVED BY THE FRENCH MEDICINE AGENCY
* STUDY WILL ENROLL 800 PATIENTS
* PRIMARY OBJECTIVE OF STUDY WILL BE TO EVALUATE EFFECT OF
MASITINIB ON TIME TO CONFIRMED DISABILITY PROGRESSION
Source text for Eikon: ID:nGNE8L50Cg
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease